The study drug is a potential new treatment for urea cycle disorders (UCD).

2 nights
5 visits

Study Objective:

  • The study drug is a potential new treatment for genetic diseases, more specifically focusing around the treatment of Recessive dystrophic epidermolysis bullosa (RDEB). Which is a serious and rare genetic skin condition that currently has no known cure.
  • The study drug is similar in it’s structure to an antibiotic known as Azithromycin.

Importance of Treatment:

  • It is hoped that the study medication can help people suffering with these rare and life threatening conditions by improving their skin integrity and the overall health of their skin, which is hoped to reduce or even stop the painful cycles of blistering and scarring they experience.

Clinical Trial Details:

  • An independent ethics committee has approved this clinical trial.
  • Participants will be reimbursed for their time

Call us on 1800 243 733 to discuss your eligibility today!


Biological Sex Male or Female
Age 18 – 55 years old
BMI 18 - 32 kg/m²
Weight <110kg
Medical History No significant medical history
Medications Not taking any prescription medication (except for hormonal contraception)
Smoking History Non-smokers and casual smokers only (<5 cigarettes/day)